Positive association between CD44 gene rs13347 C>T polymorphism and risk of cancer in Asians: a systemic review and meta-analysis
Authors Shi J, Duan Y, Pan L, Zhou X
Received 21 January 2016
Accepted for publication 13 April 2016
Published 13 June 2016 Volume 2016:9 Pages 3493—3500
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Dekuang Zhao
Peer reviewer comments 2
Editor who approved publication: Professor Min Li
Jinan Shi,1 Yin Duan,2 Lei Pan,2 Xiaoxi Zhou3
1Department of Medical Oncology, Zhejiang Hospital, 2Department of Breast Surgery, Zhejiang Provincial Traditional Chinese Medical Hospital, 3Department of Respiratory Medicine, Zhejiang Hospital, Hangzhou, Zhejiang Province, People’s Republic of China
Background: Cluster of differentiation 44 (CD44) is an important surface marker of cancer stem cells in a variety of tumors. A number of previous studies have been conducted to investigate the association between CD44 gene rs13347 C>T polymorphism and cancer risk in humans; nevertheless, the results remain controversial. We therefore performed this meta-analysis to confirm the role of this polymorphism in susceptibility to human cancer.
Materials and methods: The studies published up to December 2015 were searched in PubMed, Web of Science, and China National Knowledge Infrastructure databases. Twelve eligible case–control studies were identified, involving a total of 6,982 cases and 7,430 controls. Pooled odds ratio (OR) and corresponding 95% confidence interval (CI) were calculated using a fixed or random-effect model to estimate the strength of the association.
Results: The results of the overall analyses indicated that CD44 gene rs13347 polymorphism was significantly associated with cancer risk in Asians (CT vs CC: OR =1.35, 95% CI =1.12–1.62; TT vs CC: OR =1.99, 95% CI =1.52–2.60; TT + CT vs CC: OR =1.41, 95% CI =1.16–1.71; and TT vs CC + CT: OR =1.74, 95% CI =1.41–2.14), especially in Chinese population (CT vs CC: OR =1.42, 95% CI =1.16–1.75; TT vs CC: OR =2.13, 95% CI =1.58–2.86; TT + CT vs CC: OR =1.50, 95% CI =1.21–1.87; and TT vs CC + CT: OR =1.80, 95% CI =1.43–2.26). In stratified analyses by cancer types, there was evidence for an association between this polymorphism and nasopharyngeal cancer and breast cancer, respectively.
Conclusion: The results of this meta-analysis suggest that the CD44 gene rs13347 C>T polymorphism is associated with elevated risk of human cancer in Asians, especially in Chinese population. Further well-designed studies on a larger population covering other ethnicities should be carried out to validate our results.
Keywords: cancer, CD44, polymorphism, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]